MX2022007546A - Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. - Google Patents

Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.

Info

Publication number
MX2022007546A
MX2022007546A MX2022007546A MX2022007546A MX2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A
Authority
MX
Mexico
Prior art keywords
interferon
modified interferon
reduced immunogenicity
nucleic acid
present disclosure
Prior art date
Application number
MX2022007546A
Other languages
English (en)
Spanish (es)
Inventor
Marina Etcheverrigaray
Eduardo Federico Mufarrege
Sofía Inés Giorgetti
Groot Anne Searls De
William D Martin
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of MX2022007546A publication Critical patent/MX2022007546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022007546A 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. MX2022007546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity

Publications (1)

Publication Number Publication Date
MX2022007546A true MX2022007546A (es) 2022-11-30

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007546A MX2022007546A (es) 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.

Country Status (7)

Country Link
US (1) US20230127506A1 (https=)
EP (1) EP4076504A4 (https=)
JP (1) JP7786010B2 (https=)
AR (1) AR117715A1 (https=)
BR (1) BR112022011975A2 (https=)
MX (1) MX2022007546A (https=)
WO (1) WO2021126929A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
CN121752592A (zh) 2023-05-12 2026-03-27 再生元制药公司 干扰素受体拮抗剂及其用途
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20060062761A1 (en) * 2001-03-02 2006-03-23 Carr Francis J Modified interferon alpha with reduced immunogenicity
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
AR057215A1 (es) 2006-12-01 2007-11-21 Univ Nac Del Litoral Unl Proteina de fusion
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
AR102120A1 (es) 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
WO2019147837A2 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins

Also Published As

Publication number Publication date
AR117715A1 (es) 2021-08-25
EP4076504A1 (en) 2022-10-26
BR112022011975A2 (pt) 2022-08-30
JP2023514659A (ja) 2023-04-07
US20230127506A1 (en) 2023-04-27
WO2021126929A1 (en) 2021-06-24
EP4076504A4 (en) 2024-04-10
JP7786010B2 (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
JP2023011696A (ja) 核酸産物およびその投与方法
JP7199809B2 (ja) 核酸製品及びその投与方法
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ZA202208999B (en) Biased il2 muteins methods and compositions
US11141463B2 (en) Fusion proteins with extended serum half life
PT99565B (pt) Processo para a preparacao de factores de crescimento de fibroblastos quimerico s
AU2005283025A1 (en) Muteins of fibroblast growth factor 21
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
AU2018254410B2 (en) Optimization of enzyme replacement therapy for treatment of homocystinuria
CN110256575A (zh) 一种长效重组人生长激素融合蛋白及其工程细胞
NZ708990A (en) Method for activating helper t cell
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
PH12021553235A1 (en) Drug product for enzyme therapy for treatment of homocystinuria
CA2692358A1 (en) Recombinant human interferon-like proteins
MX2022008748A (es) Administración oral de péptidos.
PH12022553408A1 (en) Cytokine conjugates
EP0306870A2 (de) Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus
US20080200378A1 (en) KGF polypeptide compositions
KR20170024469A (ko) 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도
CN104292341B (zh) 一种凝血八因子融合蛋白及其制备方法和用途
EP3049433B1 (en) Fused proteins of granulocyte colony-stimulating factor with other partners of growth factor, preferably with stem cell factor, and method of preparation thereof
AU2002326742A1 (en) KGF polypeptide compositions